Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 17Pancreatic Neoplasms 6Neoplasm Metastasis 4Colorectal Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Recurrence 2Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Liver Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Bile Duct Neoplasms 1Advanced Gastric Cancer 1Advanced Biliary Tract Cancer 1

Interventions

Oxaliplatin 5Capecitabine 5Paclitaxel 4apatinib 3Fluorouracil 3Docetaxel 3Cisplatin 3S 1 (combination) 2Leucovorin 2titanium silicide 1rucaparib 1relatlimab 1raltitrexed 1pazopanib 1olaparib 1linrodostat 1endostar protein 1durvalumab 1dacomitinib 1capivasertib 1camrelizumab 1Sunitinib 1SHR-1701 1Nivolumab 1Ipilimumab 1HMPL-013 1Epirubicin 1Doxorubicin 1CF regimen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Gastric Cancer × titanium silicide × Clear all
NCT03137004 2017-05-08

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2 Unknown
47 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡